Serveur d'exploration Tocilizumab - Exploration (Accueil)

Index « Auteurs » - entrée « Kazuhiko Yamamoto »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Kazuhiko Tsuruya < Kazuhiko Yamamoto < Kazuhiro Araki  Facettes :

List of bibliographic references indexed by Kazuhiko Yamamoto

Number of relevant bibliographic references: 17.
Ident.Authors (with country if any)Title
000965 (2019) Masaru Kato [Japon] ; Yuko Kaneko [Japon] ; Yoshiya Tanaka [Japon] ; Masayuki Inoo [Japon] ; Hitomi Kobayashi-Haraoka [Japon] ; Koichi Amano [Japon] ; Masayuki Miyata [Japon] ; Yohko Murakawa [Japon] ; Hidekata Yasuoka [Japon] ; Shintaro Hirata [Japon] ; Hayato Nagasawa [Japon] ; Eiichi Tanaka [Japon] ; Nobuyuki Miyasaka [Japon] ; Hisashi Yamanaka [Japon] ; Kazuhiko Yamamoto [Japon] ; Isao Yokota [Japon] ; Tatsuya Atsumi [Japon] ; Tsutomu Takeuchi [Japon]Predictive value of serum amyloid a levels for requirement of concomitant methotrexate in tocilizumab initiation: A post hoc analysis of the SURPRISE study.
001141 (2018) Yuko Kaneko [Japon] ; Masaru Kato [Japon] ; Yoshiya Tanaka [Japon] ; Masayuki Inoo [Japon] ; Hitomi Kobayashi-Haraoka [Japon] ; Koichi Amano [Japon] ; Masayuki Miyata [Japon] ; Yohko Murakawa [Japon] ; Hidekara Yasuoka [Japon] ; Shintaro Hirata [Japon] ; Eiichi Tanaka [Japon] ; Nobuyuki Miyasaka [Japon] ; Hisashi Yamanaka [Japon] ; Kazuhiko Yamamoto [Japon] ; Tsutomu Takeuchi [Japon]Tocilizumab discontinuation after attaining remission in patients with rheumatoid arthritis who were treated with tocilizumab alone or in combination with methotrexate: results from a prospective randomised controlled study (the second year of the SURPRISE study).
001756 (2017) Yumi Tsuchida [Japon] ; Shuji Sumitomo [Japon] ; Hirofumi Shoda [Japon] ; Kanae Kubo [Japon] ; Keishi Fujio [Japon] ; Kazuhiko Yamamoto [Japon]Macrophage activation syndrome associated with tocilizumab treatment in adult-onset Still's disease.
001B11 (2016) Toshihiko Komai [Japon] ; Hirofumi Shoda [Japon] ; Kenichi Yamaguchi [Japon] ; Keiichi Sakurai [Japon] ; Mihoko Shibuya [Japon] ; Kanae Kubo [Japon] ; Toshiyuki Takahashi [Japon] ; Keishi Fujio [Japon] ; Kazuhiko Yamamoto [Japon]Neuromyelitis optica spectrum disorder complicated with Sjogren syndrome successfully treated with tocilizumab: A case report.
001C25 (2016) Yuko Kaneko [Japon] ; Tatsuya Atsumi [Japon] ; Yoshiya Tanaka [Japon] ; Masayuki Inoo [Japon] ; Hitomi Kobayashi-Haraoka [Japon] ; Koichi Amano [Japon] ; Masayuki Miyata [Japon] ; Yohko Murakawa [Japon] ; Hidekata Yasuoka [Japon] ; Shintaro Hirata [Japon] ; Hayato Nagasawa [Japon] ; Eiichi Tanaka [Japon] ; Nobuyuki Miyasaka [Japon] ; Hisashi Yamanaka [Japon] ; Kazuhiko Yamamoto [Japon] ; Tsutomu Takeuchi [Japon]Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study).
001E94 (2015) Atsushi Ogata [Japon] ; Tatsuya Atsumi [Japon] ; Takaaki Fukuda [Japon] ; Yasuhiko Hirabayashi [Japon] ; Masaaki Inaba [Japon] ; Naoki Ishiguro [Japon] ; Motokazu Kai [Japon] ; Daisuke Kawabata [Japon] ; Daihei Kida [Japon] ; Hitoshi Kohsaka [Japon] ; Ryutaro Matsumura [Japon] ; Seiji Minota [Japon] ; Masaya Mukai [Japon] ; Takayuki Sumida [Japon] ; Kiyoshi Takasugi [Japon] ; Shigenori Tamaki [Japon] ; Tsutomu Takeuchi [Japon] ; Atsuhisa Ueda [Japon] ; Kazuhiko Yamamoto [Japon] ; Hisashi Yamanaka [Japon] ; Hajime Yoshifuji [Japon] ; Akira Nomura [Japon]Sustainable Efficacy of Switching From Intravenous to Subcutaneous Tocilizumab Monotherapy in Patients With Rheumatoid Arthritis.
001F54 (2015) Yu Funakubo Asanuma [Japon] ; Toshihide Mimura ; Hiroto Tsuboi ; Hisashi Noma ; Fumihiko Miyoshi ; Kazuhiko Yamamoto ; Takayuki SumidaNationwide epidemiological survey of 169 patients with adult Still's disease in Japan.
001F69 (2015) Kazuhiko Yamamoto [Japon] ; Hajime Goto ; Kenzo Hirao ; Atsuo Nakajima ; Hideki Origasa ; Kunihiko Tanaka ; Minako Tomobe ; Kyoichi TotsukaLongterm Safety of Tocilizumab: Results from 3 Years of Followup Postmarketing Surveillance of 5573 Patients with Rheumatoid Arthritis in Japan.
002257 (2015) Chak Sing Lau [Hong Kong] ; Faith Chia [Singapour] ; Andrew Harrison [Nouvelle-Zélande] ; Tsu-Yi Hsieh [Taïwan] ; Rahul Jain [Inde] ; Seung Min Jung [Corée du Sud] ; Mitsumasa Kishimoto [Japon] ; Ashok Kumar [Inde] ; Khai Pang Leong [Singapour] ; Zhanguo Li [République populaire de Chine] ; Juan Javier Lichauco [Philippines] ; Worawit Louthrenoo [Thaïlande] ; Shue-Fen Luo [Taïwan] ; Peter Nash [Australie] ; Chin Teck Ng [Singapour] ; Sung-Hwan Park [Corée du Sud] ; Bagus Putu Putra Suryana [Indonésie] ; Parawee Suwannalai [Thaïlande] ; Linda Kurniaty Wijaya [Indonésie] ; Kazuhiko Yamamoto [Japon] ; Yue Yang [République populaire de Chine] ; Swan Sim Yeap [Malaisie]APLAR rheumatoid arthritis treatment recommendations
002297 (2014) Saori Sakaue [Japon] ; Shuji Sumitomo [Japon] ; Kanae Kubo [Japon] ; Keishi Fujio [Japon] ; Kazuhiko Yamamoto [Japon]Tocilizumab-induced leucocytoclastic vasculitis in a patient with rheumatoid arthritis.
002698 (2013) Mihoko Shibuya [Japon] ; Keishi Fujio ; Kaoru Morita ; Hiroaki Harada ; Hiroko Kanda ; Kazuhiko YamamotoSuccessful treatment with tocilizumab in a case of Cogan's syndrome complicated with aortitis.
002769 (2013) Yukinori Okada [États-Unis] ; Di Wu [États-Unis, Australie] ; Gosia Trynka [États-Unis] ; Towfique Raj [États-Unis] ; Chikashi Terao [Japon] ; Katsunori Ikari [Japon] ; Yuta Kochi [Japon] ; Koichiro Ohmura [Japon] ; Akari Suzuki [Japon] ; Shinji Yoshida [Japon] ; Robert R. Graham [États-Unis] ; Arun Manoharan [États-Unis] ; Ward Ortmann [États-Unis] ; Tushar Bhangale [États-Unis] ; Joshua C. Denny [États-Unis] ; Robert J. Carroll [États-Unis] ; Anne E. Eyler [États-Unis] ; Jeffrey D. Greenberg [États-Unis] ; Joel M. Kremer [États-Unis] ; Dimitrios A. Pappas [États-Unis] ; Lei Jiang [République populaire de Chine] ; Jian Yin [République populaire de Chine] ; Lingying Ye [République populaire de Chine] ; Ding-Feng Su [République populaire de Chine] ; Jian Yang [Australie] ; Gang Xie [Canada] ; Ed Keystone [Canada] ; Harm-Jan Westra [Pays-Bas] ; T Nu Esko [Estonie, États-Unis] ; Andres Metspalu [Estonie] ; Xuezhong Zhou [République populaire de Chine] ; Namrata Gupta [États-Unis] ; Daniel Mirel [États-Unis] ; Eli A. Stahl [États-Unis] ; Dorothée Diogo [États-Unis] ; Jing Cui [États-Unis] ; Katherine Liao [États-Unis] ; Michael H. Guo [États-Unis] ; Keiko Myouzen [Japon] ; Takahisa Kawaguchi [Japon] ; Marieke J. H. Coenen [Pays-Bas] ; Piet L. C. M. Van Riel [Pays-Bas] ; Mart A. F. J. Van De Laar [Pays-Bas] ; Henk-Jan Guchelaar [Pays-Bas] ; Tom W. J. Huizinga [Pays-Bas] ; Philippe Dieudé [France] ; Xavier Mariette [France] ; S. Louis Bridges [États-Unis] ; Alexandra Zhernakova [Pays-Bas] ; Rene E. M. Toes [Pays-Bas] ; Paul P. Tak [Pays-Bas, Royaume-Uni] ; Corinne Miceli-Richard [France] ; So-Young Bang [Corée du Sud] ; Hye-Soon Lee [Corée du Sud] ; Javier Martin [Espagne] ; Miguel A. Gonzalez-Gay [Espagne] ; Luis Rodriguez-Rodriguez [Espagne] ; Solbritt Rantap Dahlqvist [Suède] ; Lisbeth Rlestig [Suède] ; Hyon K. Choi [États-Unis] ; Yoichiro Kamatani [France] ; Pilar Galan [France] ; Mark Lathrop [Canada] ; Steve Eyre [Royaume-Uni] ; John Bowes [Royaume-Uni] ; Anne Barton [Royaume-Uni] ; Niek De Vries [Pays-Bas] ; Larry W. Moreland [États-Unis] ; Lindsey A. Criswell [États-Unis] ; Elizabeth W. Karlson [États-Unis] ; Atsuo Taniguchi [Japon] ; Ryo Yamada [Japon] ; Michiaki Kubo [Japon] ; Jun S. Liu [États-Unis] ; Sang-Cheol Bae [Corée du Sud] ; Jane Worthington [Royaume-Uni] ; Leonid Padyukov [Suède] ; Lars Klareskog [Suède] ; Peter K. Gregersen [États-Unis] ; Soumya Raychaudhuri [États-Unis, Royaume-Uni] ; Barbara E. Stranger [États-Unis] ; Philip L. De Jager [États-Unis] ; Lude Franke [Pays-Bas] ; Peter M. Visscher [Australie] ; Matthew A. Brown [Australie] ; Hisashi Yamanaka [Japon] ; Tsuneyo Mimori [Japon] ; Atsushi Takahashi [Japon] ; Huji Xu [République populaire de Chine] ; Timothy W. Behrens [États-Unis] ; Katherine A. Siminovitch [Canada] ; Shigeki Momohara [Japon] ; Fumihiko Matsuda [Japon] ; Kazuhiko Yamamoto [Japon] ; Robert M. Plenge [États-Unis]Genetics of rheumatoid arthritis contributes to biology and drug discovery
002867 (2013) Tsutomu Takeuchi [Japon] ; Masayoshi Harigai [Japon] ; Yoshiya Tanaka [Japon] ; Hisashi Yamanaka [Japon] ; Naoki Ishiguro [Japon] ; Kazuhiko Yamamoto [Japon] ; Nobuyuki Miyasaka [Japon] ; Takao Koike [Japon] ; Minoru Kanazawa [Japon] ; Takuya Oba [Japon] ; Toru Yoshinari [Japon] ; Daniel Baker [États-Unis]Golimumab monotherapy in Japanese patients with active rheumatoid arthritis despite prior treatment with disease-modifying antirheumatic drugs: results of the phase 2/3, multicentre, randomised, double-blind, placebo-controlled GO-MONO study through 24 weeks
003C55 (2010) Jun Hashimoto [Japon] ; Patrick Garnero [France] ; Désirée Van Der Heijde [Pays-Bas] ; Nobuyuki Miyasaka [Japon] ; Kazuhiko Yamamoto [Japon] ; Shinichi Kawai [Japon] ; Tsutomu Takeuchi [Japon] ; Hideki Yoshikawa [Japon] ; Norihiro Nishimoto [Japon]Humanized anti-interleukin-6-receptor antibody (tocilizumab) monotherapy is more effective in slowing radiographic progression in patients with rheumatoid arthritis at high baseline risk for structural damage evaluated with levels of biomarkers, radiography, and BMI: data from the SAMURAI study
003F02 (2009) Norihiro Nishimoto [Japon] ; Nobuyuki Miyasaka ; Kazuhiko Yamamoto ; Shinichi Kawai ; Tsutomu Takeuchi ; Junichi Azuma ; Tadamitsu KishimotoStudy of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy.
003F33 (2009) Jun Hashimoto [Japon] ; Patrick Garnero ; Désirée Van Der Heijde ; Nobuyuki Miyasaka ; Kazuhiko Yamamoto ; Shinichi Kawai ; Tsutomu Takeuchi ; Hideki Yoshikawa ; Norihiro NishimotoA combination of biochemical markers of cartilage and bone turnover, radiographic damage and body mass index to predict the progression of joint destruction in patients with rheumatoid arthritis treated with disease-modifying anti-rheumatic drugs.
004193 (2007) Norihiro Nishimoto [Japon] ; Jun Hashimoto [Japon] ; Nobuyuki Miyasaka [Japon] ; Kazuhiko Yamamoto [Japon] ; Shinichi Kawai [Japon] ; Tsutomu Takeuchi [Japon] ; Norikazu Murata [Japon] ; Désirée Van Der Heijde [Pays-Bas] ; Tadamitsu Kishimoto [Japon]Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Main/Exploration
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/Author.i -k "Kazuhiko Yamamoto" 
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/Author.i  \
                -Sk "Kazuhiko Yamamoto" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    Main
   |étape=   Exploration
   |type=    indexItem
   |index=    Author.i
   |clé=    Kazuhiko Yamamoto
}}

Wicri

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021